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of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, VA, USA.

RESULTS

INTRODUCTION
•
•
•
•

Chronic obstructive pulmonary disease (COPD) is the third
leading cause of death worldwide and one-third of COPD
patients die of cardiovascular disease (CVD)
Arterial stiffness (AS) assessments through pulse wave analysis
and velocity are non-invasive, valid and reliable measurements
to assess cardiovascular health
6-minute walk test (6MWT), a cardiorespiratory fitness measure,
is a clinically meaningful predictor of COPD mortality
The naturally occurring antioxidant resveratrol has improved
cardiovascular health in other populations

Table 1. Participants Characteristics

Six Weeks of Resveratrol Improves 6MWT Variables in COPD

PURPOSE
The purpose of this pilot study was to test if six-weeks of
resveratrol supplementation could improve cardiovascular health
in patients with COPD.

METHODS
Subjects. A randomized, double-blind, placebo-controlled trial was
completed in 7 participants (Table 1) previously diagnosed with
COPD. Subject data was further divided into treatment (resveratrol)
and control groups.

Values are mean ± STDEV. M= Males; F= Females; C=Caucasian; AA= African
American; BMI= Body mass index; SBP= Systolic blood pressure; DBP=
Diastolic blood pressure; HR= Heart rate; SpO2= Peripheral capillary oxygen
saturation

Six Weeks of Resveratrol Improves Arterial Stiffness Variables in COPD

Cardiovascular Health Assessment: Pulse wave analysis (PWA) and
pulse wave velocity (PWV) (Sphygmocor XCEL, Atcor) were used to
noninvasively assess variables of cardiovascular health and arterial
stiffness. For PWA, a blood pressure cuff was placed on the upperarm over the brachial artery and measured in replicate to evaluate
CV health variables. For PWV, a blood pressure cuff was placed on
the participants thigh over the femoral artery and a probe was
placed on the carotid artery to analyze
pulse velocity (Figure 1). For 6MWT,
participants were asked to walk for six
minutes with assistance if necessary.
Variables such as blood pressure, heart rate,
dyspnea, fatigue, and SpO2 were measured
Figure 1. Representative
before, during, and after the test.
example of PWA/PWV testing

CONCLUSION

Statistical Analysis. Measurements are expressed as mean and
standard deviation (SD) unless denoted otherwise. Differences
between placebo and treatment were analyzed using students ttests and considered statistically significant when p <0.05.

Our results suggest that six weeks of supplementation with resveratrol improves markers of
cardiovascular health and fitness in patients with COPD. This data implies that resveratrol has potential to
be used as a therapy in patients with COPD to mitigate CVD risk. Future studies are warranted to expand
this pilot study and understand the potential role of resveratrol in COPD cardiovascular health.
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